TIDMAKR
RNS Number : 0430L
Akers Biosciences, Inc.
14 July 2017
July 14, 2017
This announcement contains inside information
Akers Biosciences, Inc.
Notice of Annual General Meeting
&
Proposed Directorate Changes
Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (the
"Company" or "Akers Bio"), a developer of rapid health information
technologies, announces that a notice convening an Annual General
Meeting ("AGM") of the Company (the "Notice") will shortly be sent
to all shareholders and will be available in the US SEC Filings
section on the Company's website at www.akersbio.com.
The AGM will be held on August 7, 2017, at 4:00 P.M. EST at 50
South 16th Street, Suite 2710, Philadelphia, PA 19106, USA.
Among the proposals contained in the Notice are the nominations
for election to the board of directors of three new non-executive
directors, Bill J. White, Richard C. Tarbox III and Christopher C.
Schreiber; together with the nomination for election to the board
of directors of John J. Gormally, Chief Executive Officer.
Currently, Mr. Gormally is not a director of the Company. The
Notice also proposes that Raymond F. Akers Jr., a current executive
director of the Company and its Vice Chairman, be re-elected as a
director of the Company; and it is anticipated that Dr. Akers will
become Executive Chairman upon his re-election as a director.
Thomas J. Knox., the current Non-executive Chairman of the
Company; and Robert E. Andrews, Brandon Knox and Raza Bokhari, all
non-executive directors of the Company, are not standing for
re-election at the AGM and will retire from the board upon the
election of the new directors. The board would like to place on
record its thanks to the outgoing directors for their significant
contributions to the development of the Company.
Biographies of the nominated new directors
John J. Gormally
Mr. Gormally has served as the Company's Chief Executive Officer
since appointed to the position on November 16, 2015. Mr. Gormally
has over 30 years of experience as a member of senior management in
the healthcare industry. He joined Becton, Dickinson and Company
("Becton"), a medical technology company that manufactures and
sells a range of medical supplies and diagnostic equipment, in 1978
as a senior sales representative. Mr. Gormally served in a wide
range of positions with Becton through 2013, focusing primarily on
commercialization of Becton's products and fostering sales growth.
From 1999 to 2001, Mr. Gormally served as the Vice President of
U.S. Sales and Operations for ConvaTec, a former division of
Bristol-Myers Squibb Company. From 2001 to 2002, he served as the
Vice President of Global Sales and Marketing for BEI Medical
Systems Company, Inc., prior to rejoining Becton from 2002 to 2013.
In 2013, Mr. Gormally founded Gormally Elite Medical LLC, a
healthcare consulting firm that specializes in human resources and
developing go-to-market commercialization strategies.
Mr. Gormally earned an undergraduate degree from DeSales
University in 1978 and is currently an MBA candidate at
Northeastern University.
Mr. Gormally was selected to serve on the board in part because
of his significant experience of running companies operating in the
medical device area.
Bill J. White
Mr. White has more than 30 years of experience in financial
management, operations and business development. He currently
serves as Chief Financial Officer, Treasurer and Secretary of
Intellicheck Mobilisa, Inc., a technology company listed on the
NYSE MKT. Prior to working at Intellicheck Mobilisa, Inc., he
served 11 years as the Chief Financial Officer, Secretary and
Treasurer of FocusMicro, Inc. ("FM"). As co-founder of FM, Mr.
White played an integral role in growing the business from the
company's inception to over $36 million in annual revenue in a
five-year period. Mr. White has broad domestic and international
experience including managing rapid and significant growth,
import/export, implementing tough cost management initiatives,
exploiting new growth opportunities, merger and acquisitions,
strategic planning, resource allocation, tax compliance and
organization development. Prior to co-founding FM, he served 15
years in various financial leadership positions in the government
sector. Mr. White started his career in Public Accounting.
Mr. White holds a Bachelor of Arts in Business Administration
from Washington State University and is a Certified Fraud
Examiner.
Mr. White was selected to serve on the board in part because of
his significant financial and accounting experience with public
companies.
Richard C. Tarbox III
Mr. Tarbox III combines over 40 years of management experience
in the medical device and diagnostics sector of the healthcare
industry. Mr. Tarbox presently serves as a registered investment
banker at Aquilo Partners, L.P., focusing his practice on the needs
of clients in the life science tools and diagnostics sectors.
Previously, he held executive roles, primarily in business
development and operations management, with Becton Dickinson,
Thermo Fisher Scientific, Cardinal Health, Baxter International
Inc. and American Hospital Supply Corporation. He has also served a
number of companies in the industry as an officer and member of the
board of directors including: Alverix, Inc., as Chief Executive
Officer and board member from 2010 to 2014, Quidel Corporation, as
Chief Development Officer from 2007 to 2009, ClearData Networks, as
Chief Operating Officer and a board member from 1999 to 2001,
Bioseparations Inc., as Chief Executive Officer and a board member
from 1995 to 1998, Metrika Laboratories, as a board member from
1994 to 1995, DenOptix, Inc., as a board member from 1995 to 1998
and Ostex International Inc., as Chief Operating Officer from 1992
to 1995. Mr. Tarbox currently serves as a member of the advisory
boards of Qorvo Inc. and Safeguard Scientifics, Inc.
Mr. Tarbox is a graduate of the University of Washington, where
he received his Bachelor's Degree in Clinical Psychology and the
Kellogg School of Management at Northwestern University where he
earned a Master's degree in Business Management.
Mr. Tarbox was selected to serve on the board in part because of
his significant experience in the medical device and diagnostics
industry, as well as his management experience.
Christopher C. Schreiber
Mr. Schreiber combines over 30 years of experience in the
securities industry. As the Managing Director of Capital Markets at
Taglich Brothers, Inc., Mr. Schreiber builds upon his extensive
background in capital markets, deal structures, and syndications.
Prior to his time at Taglich Brothers, he was a member of the board
of directors of Paulson Investment Company, a 40-year-old full
service Investment Banking firm. In addition, Mr. Schreiber serves
has a director and partner of Long Island Express North, an elite
lacrosse training organization for teams and individuals. He also
volunteers on the board of directors for Fox Lane Youth Lacrosse, a
community youth program.
Mr. Schreiber is a graduate of John Hopkins University, where he
received his Bachelor's Degree in Political Science.
Mr. Schreiber was selected to serve on the board in part because
of his significant experience in capital markets and knowledge of
the Company.
AIM Rules disclosures
The following disclosures are required to be made in accordance
with Rule 17, Schedule Two (g) of the AIM Rules for Companies in
respect of the proposed appointments of John J. Gormally (aged 61),
Billy Joe White (aged 56), Richard Carlyle Tarbox III (aged 65) and
Christopher Charles Schreiber (aged 52).
Director Current directorships Directorships held
in the last 5 years
John J. Gormally Velano Vascular -
Inc
Board of Directors
for Franciscan
Sisters of the
Poor
Gormally Elite
Medical LLC
Bill J. White - MicroPhase Corp
Richard C. Tarbox - Alverix Inc.
III Aquilo Partners
LP
Christopher - Paulson Investment
C. Schreiber Company
Richard C. Tarbox III was a director of ClearDATA.net in 2000
when the company entered into the voluntary filing of Chapter 11.
The company was subsequently reorganized and is presently trading
as ClearDATA Networks, Inc.
John J. Gormally holds 30,000 shares in the Company representing
approximately 0.34% of the Company's issued share capital.
About Akers Biosciences, Inc.
Akers Bio develops, manufactures, and supplies rapid screening
and testing products designed to deliver quicker and more
cost-effective healthcare information to healthcare providers and
consumers. The Company has advanced the science of diagnostics
while responding to major shifts in healthcare through the
development of several proprietary platform technologies. The
Company's state-of-the-art rapid diagnostic assays can be performed
virtually anywhere in minutes when time is of the essence. The
Company has aligned with major healthcare companies and high volume
medical product distributors to maximize product offerings, and to
be a major worldwide competitor in diagnostics.
Additional information on the Company and its products can be
found at www.akersbio.com. Follow us on Twitter @AkersBio.
Cautionary Statement Regarding Forward Looking Statements
Statements contained herein that are not based upon current or
historical fact are forward-looking in nature and constitute
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. Such forward-looking statements reflect the Company's
expectations about its future operating results, performance and
opportunities that involve substantial risks and uncertainties.
These statements include but are not limited to statements
regarding the intended terms of the offering, closing of the
offering and use of any proceeds from the offering. When used
herein, the words "anticipate," "believe," "estimate," "upcoming,"
"plan," "target", "intend" and "expect" and similar expressions, as
they relate to Akers Biosciences, Inc., its subsidiaries, or its
management, are intended to identify such forward-looking
statements. These forward-looking statements are based on
information currently available to the Company and are subject to a
number of risks, uncertainties, and other factors that could cause
the Company's actual results, performance, prospects, and
opportunities to differ materially from those expressed in, or
implied by, these forward-looking statements.
The information communicated in this announcement is inside
information for the purposes of Article 7 of Regulation
596/2014.
For more information:
Akers Biosciences, Inc.
John J. Gormally, Chief Executive Officer
Raymond F. Akers, Jr. PhD, Vice Chairman
Tel. +1 856 848 8698
finnCap (UK Nominated Adviser and Broker)
Adrian Hargrave / Scott Mathieson (Corporate Finance)
Steve Norcross (Broking)
Tel. +44 (0)20 7220 0500
Vigo Communications (Global Public Relations)
Ben Simons / Fiona Henson
Tel. +44 (0)20 7830 9704
Email: akers@vigocomms.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NOAOKNDQPBKDFOD
(END) Dow Jones Newswires
July 14, 2017 02:00 ET (06:00 GMT)
Akers Biosciences (LSE:AKR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Akers Biosciences (LSE:AKR)
Historical Stock Chart
From Apr 2023 to Apr 2024
